Life Sciences Real World Evidence Market

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the real world evidence market in the short-mid term and long term.

Chapter 3 is an introductory chapter that presents a general overview of investment required for developing new medical products, along with information on the limitations associated with randomized clinical trials. Further, it features a detailed discussion on the growing importance of real world evidence and its potential to complement RCTs in healthcare decision-making. It also includes a description of how real world evidence insights is generated from raw, unstructured data, along with details on different sources of data, and the potential applications of this novel approach. Further, the chapter features a discussion on the key growth drivers and roadblocks related to real world evidence, and the novel technologies that are likely to have a notable impact on this industry’s evolution over the coming decade.

Chapter 4 provides a detailed description on the primary elements of data governance and regulatory framework related to real world evidence across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific and rest of the world (Australia, China and Japan).

Chapter 5 provides a detailed assessment of the industry players that claim to offer real world evidence solutions. The chapter presents analysis of these players on the basis of the year of establishment, company size (in terms of number of employees), location of headquarters, type of services offered (real world data, analytics, consulting and services), real world data sources (medical claims, clinical trials, clinical setting, pharmacy, patient-powered and others), and target application areas (early stage research, clinical development, regulatory submission / reimbursement / market access, and post-approval studies).

Chapter 6 features profiles of prominent real world evidence service providers. Each company profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective portfolio of technologies / platforms / services, recent developments and an informed future outlook.

Chapter 7 presents a detailed geographical clinical trial analysis of completed, ongoing and planned studies conducted in the real world setting based on the multiple parameters, such as current trial status, trial registration year, regional distribution, enrolled patient population, type of study, leading industry and non-industry players, emerging focus areas and key therapeutic areas. It also highlights the clinical trials conducted for the novel COVID-19 disease. Further, it presents a benchmarking analysis of the leading industry players (in terms of the number of trials conducted). 

Chapter 8 provides information on certain recent publications that we came across during our research on real world evidence. This chapter features a detailed analysis the key prevalent trends associated with these publications, including information on type of publication, year of publication, study objective, popular keywords, types of real world datasets utilized, key disease indications, type of publisher, leading players (in terms of number of publications), region, and key journals (in terms of number of articles published in this domain and impact factor of the journal) to offer better insights on the emerging trends in this area. 

Chapter 9 provides insights on the popularity of real world evidence on the social media platform, Twitter. The chapter highlights the yearly distribution of tweets posted on the platform in the last few years and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter showcases the most frequently mentioned keywords, real world data sources, target applications, therapeutic areas and players, on the social media platform. It elucidates the most prolific authors and presents a bubble analysis of the most influential authors related to real world evidence on Twitter.

Chapter 10 presents the insights obtained from a detailed analysis of the events organized for stakeholders in this domain. In addition, the chapter provides details on the different agendas of the summits / forums / conferences / workshops that have been conducted over the last few years or are planned to be held in the coming years.  The analyses presented in the chapter are based on different parameters related to the shortlisted global events, such as the date of event, location, type of event and focus area, organizer, and most active stakeholders, and designations / affiliated departments of the participants. 

Chapter 11 presents information on the needs of different stakeholders (manufacturers, regulators, payers, providers and patients) involved in this domain. The chapter qualitatively assesses the real world evidence related needs of each stakeholder group and the relative importance of their expectations within this domain.

Chapter 12 provides a detailed acquisition target analysis, taking into consideration the historical trend of the activity of the companies that have acquired other firms, and offering a means for other industry stakeholders to identify potential acquisition targets.

Chapter 13 provides details on the key parameters and trends that are likely to influence the future of the real world evidence market, under a comprehensive SWOT framework. The chapter also features a schematic Harvey ball analysis to highlight the relative impact of each SWOT parameter on the overall real world evidence market.

Chapter 14 provides a comprehensive list of notable real world evidence use cases of pharmaceutical / medical device companies in the recent past (since 2016). The chapter highlights how these companies leveraged real world evidence to support their regulatory decisions, advance disease understanding and clinical guidelines, and assist outcome-based reimbursement decisions. In addition, the chapter presents an insightful opportunity analysis, estimating the existing market size and potential growth opportunities of real world evidence across different applications (early stage research, clinical development, regulatory approval, pricing / reimbursement, and post-approval studies). Based on multiple parameters, such as number of pre- or post-approval studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2021-2030. In addition, the report provides detailed market segmentation on the basis of type of real world data sources (medical claims, clinical trials, clinical setting, patient-powered and other data sources), therapeutic area (autoimmune disorders, cardiovascular disorders, infectious diseases, metabolic disorders, neurological / psychiatric disorders, oncological disorders, respiratory disorders and other disorders), and the geographical distribution of the market (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World). 

Chapter 15 presents the insights generated from a detailed survey, wherein we invited multiple stakeholders involved in the real world evidence domain. The participants, who were primarily Directors / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their offerings and the associated commercial potential.

Chapter 16 highlights the impact of COVID-19 outbreak on the real world evidence market. In addition, it features a brief discussion on the key initiatives undertaken by players.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.

Chapter 18 is a collection of transcripts of interviews conducted with various key stakeholders during the course of this study. We have presented the details of our discussions with Limor BH Epstein (Founder, Data2Life), Anonymous (Vice President, Big Pharmaceutical Company), Wirth Peter (Vice President, RTI Health Solutions), Douglas Drake (Senior Director, Clinerion), Fernando Santa (Chief Operating Officer, Adarna Health Data), Jonathan Moshinsky (Chief Strategy Officer, uMotif), and Anonymous (Savana).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Need for Real World Evidence
3.2.1. Growing Concerns Related to Chronic Disorders
3.2.2. High Investments in Drug Development
3.2.3. Role of Randomized Clinical Trials
3.2.4. Shift from Volume- to Value-based Care

3.3. Overview of Real World Evidence
3.3.1. Sources of Real World Data
3.3.1.1. Medical Claims Data
3.3.1.2. Clinical Trial Data
3.3.1.3. Patient-powered Data
3.3.1.4. Pharmacy Data
3.3.1.5. Other Real World Data Sources

3.3.2. Comparison of Randomized Clinical Trials and Real World Evidence
3.3.3. Advantages and Limitations of Real World Evidence
3.3.4. Potential Applications of Real World Evidence
3.3.5. Growth Drivers and Challenges

3.4. Role of Advanced Techniques in Real World Data Management
3.5. Future Perspectives

4. DATA GOVERNANCE AND REGULATORY FRAMEWORK FOR REAL WORLD EVIDENCE
4.1. Chapter Overview
4.2. Primary Elements of Data Governance for Real World Evidence
4.3. Importance of Regulatory Framework for Real World Evidence

4.4. Data Governance and Regulatory Framework in North America
4.4.1. The US Scenario
4.4.1.1. Data Governance
4.4.1.2. Regulatory Framework

4.4.2. The Canadian Scenario
4.4.2.1. Data Governance
4.4.2.2. Regulatory Framework

4.5. Data Governance and Regulatory Framework in Europe
4.5.1. The UK Scenario
4.5.1.1. Data Governance
4.5.1.2. Regulatory Framework

4.5.2. The German Scenario
4.5.2.1. Data Governance
4.5.2.2. Regulatory Framework

4.5.3. The French Scenario
4.5.3.1. Data Governance
4.5.3.2. Regulatory Framework

4.5.4. The Spanish Scenario
4.5.5. The Italian Scenario

4.6. Data Governance and Regulatory Framework in Asia-Pacific and Rest of the World
4.6.1. The Australian Scenario
4.6.2. The Chinese Scenario
4.6.3. The Japanese Scenario

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Real World Evidence Solution Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Business Model
5.2.5. Analysis by Type of Services Offered
5.2.6. Analysis by Real World Data Source
5.2.7. Analysis by Key Applications of Real World Evidence
5.2.8. Analysis by Key Therapeutic Areas

6. COMPANY PROFILES 
6.1. Chapter Overview
6.2. Clinerion
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.3. Recent Developments and Future Outlook

6.3. Clinigen Group
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. Cognizant Analytics
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Evidera
6.5.1. Company Overview
6.5.2. Technology Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. HealthCore
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook

6.7. IBM
6.7.1. Company Overview
6.7.2. Technology Portfolio
6.7.3. Recent Developments and Future Outlook

6.8. ICON
6.8.1. Company Overview
6.8.2. Technology Portfolio
6.8.3. Recent Developments and Future Outlook

6.9. IQVIA
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Recent Developments and Future Outlook

6.10. Medpace
6.10.1. Company Overview
6.10.2. Technology Overview
6.10.3. Recent Developments and Future Outlook

6.11. NorthWest EHealth
6.11.1. Company Overview
6.11.2. Technology Overview
6.11.3. Recent Developments and Future Outlook

6.12. Optum Insight
6.12.1. Company Overview
6.12.2. Recent Developments and Future Outlook

6.13. Oracle
6.13.1. Company Overview
6.13.2. Technology Portfolio
6.13.3. Recent Developments and Future Outlook
6.14. PAREXEL
6.14.1. Company Overview
6.14.2. Technology Overview
6.14.3. Recent Developments and Future Outlook

6.15. Perkin Elmer
6.15.1. Company Overview
6.15.2. Recent Developments and Future Outlook

6.16. SAS
6.16.1. Company Overview
6.16.2. Technology Portfolio
6.16.3. Recent Developments and Future Outlook

6.17. Syneos Health
6.17.1. Company Overview
6.17.2. Recent Developments and Future Outlook

6.18. TriNetX
6.18.1. Company Overview
6.18.2. Technology Overview
6.18.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS 
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Real World Evidence: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Recruitment Status
7.3.3. Analysis by Type of Study
7.3.4. Analysis by Type of Sponsor / Collaborator
7.3.5. Most Active Players: Analysis by Number of Trials
7.3.6. Geographical Analysis by Number of Clinical Trials
7.3.7. Geographical Analysis by Enrolled Patient Population
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Key Therapeutic Areas
7.3.10. Grid Representation: Analysis by Key Therapeutic Areas, Number of Trials and Leading Players
7.3.11. Benchmark Analysis of Key Industry Players

8. PUBLICATION ANALYSIS 
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. Real World Evidence: Recent Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Emerging Focus Areas
8.3.3. Analysis by Real World Data Sources
8.3.4. Analysis by Key Indications Examined
8.3.5. Leading Players: Analysis by Number of Publications
8.3.6. Geographical Analysis by Number of Publications

8.3.7. Analysis by Key Research Journals
8.3.7.1. Key Journals: Analysis by Number of Publications
8.3.7.2. Key Journals: Analysis by Journal Impact Factor

8.3.8. Most Popular Authors: Analysis by Number of Publications

9. EMERGING TRENDS ON SOCIAL MEDIA
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Real World Evidence: Trends on Twitter
9.3.1. Historical Trends in Volume of Tweets
9.3.2. Popular Keywords
9.3.3. Popular Real World Data Sources
9.3.4. Popular Applications of Real World Evidence
9.3.5. Popular Therapeutic Areas
9.3.6. Popular Stakeholders
9.3.7. Most Prolific Contributors
9.3.8. Most Influential Contributors

10. GLOBAL EVENTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Real World Evidence: Global Events Analysis
10.3.1. Analysis by Year of Occurrence
10.3.2. Analysis by Event Platform
10.3.3. Analysis by Type of Event 
10.3.4. Analysis by Geography 
10.3.5. Evolutionary Trends in Key Focus Area / Event Agenda
10.3.6. Most Active Event Organizers
10.3.7. Most Active Participants: Analysis by Number of Events
10.3.8. Analysis by Seniority Level of Participants
10.3.9. Geographical Mapping of Upcoming Events

11. STAKEHOLDER NEEDS ANALYSIS
11.1. Chapter Overview
11.2. Real World Evidence: Approaches for Data Generation
11.3. Real World Evidence: Needs of Different Stakeholders
11.4. Real World Evidence: Comparison of Needs of Various Stakeholders
11.4.1. Needs of Healthcare Providers
11.4.2. Needs of Manufacturers
11.4.3. Needs of Payers
11.4.4. Needs of Patients
11.4.5. Needs of Regulators

12. KEY ACQUISITION TARGETS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Scoring Criteria and Key Assumptions
12.4. Potential Strategic Acquisition Targets in North America
12.5. Potential Strategic Acquisition Targets in Europe
12.6. Potential Strategic Acquisition Targets in Asia-Pacific and Rest of the World
12.7. Concluding Remark

13. SWOT ANALYSIS
13.1. Chapter Overview
13.2. Real World Evidence: SWOT Analysis
13.2.1. Comparison of SWOT Factors

14. COST SAVING AND MARKET OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Real World Evidence Use Cases
14.3. Real World Evidence Market Opportunity Assessment
14.3.1 Methodology and Key Assumptions

14.4. Overall Real World Evidence Market Opportunity in Drug Development, 2021-2030
14.4.1. Real World Evidence Market Opportunity across Different Type of Sources
14.4.1.1. Real World Evidence Market Opportunity from Medical Claims Data, 2021-2030
14.4.1.2. Real World Evidence Market Opportunity from Clinical Trials Data, 2021-2030
14.4.1.3. Real World Evidence Market Opportunity from Clinical Settings Data, 2021-2030
14.4.1.4. Real World Evidence Market Opportunity from Patient-Powered Data, 2021-2030
14.4.1.5. Real World Evidence Market Opportunity from Other Types of Data, 2021-2030

14.4.2. Overall Real World Evidence Market Opportunity across Different Therapeutic
14.4.2.1. Real World Evidence Market Opportunity for Autoimmune Disorders, 2021-2030
14.4.2.2. Real World Evidence Market Opportunity for Cardiovascular Disorders, 2021-2030
14.4.2.3. Real World Evidence Market Opportunity for Infectious Diseases, 2021-2030
14.4.2.4. Real World Evidence Market Opportunity for Metabolic Disorders, 2021-2030
14.4.2.5. Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, 2021-2030
14.4.2.6. Real World Evidence Market Opportunity for Oncological Disorders, 2021-2030
14.4.2.7. Real World Evidence Market Opportunity for Respiratory Disorders, 2021-2030
14.4.2.8. Real World Evidence Market Opportunity for Other Disorders, 2021-2030

14.4.3. Overall Real World Evidence Market Opportunity across Different Areas of
14.4.3.1. Real World Evidence Market Opportunity in Early Stage Research, 2021-2030
14.4.3.2. Real World Evidence Market Opportunity in Clinical Development, 2021-2030
14.4.3.3. Real World Evidence Market Opportunity in Regulatory Approval, 2021-2030
14.4.3.4. Real World Evidence Market Opportunity in Pricing / Reimbursement, 2021-2030
14.4.3.5. Real World Evidence Market Opportunity in Post-Approval Studies, 2021-2030

14.4.4. Overall Real World Evidence Market Opportunity across Different Geographies
14.4.4.1. Real World Evidence Market Opportunity in North America, 2021-2030
14.4.4.2. Real World Evidence Market Opportunity in Europe, 2021-2030
14.4.4.3. Real World Evidence Market Opportunity in Asia-Pacific, 2021-2030
14.4.4.4. Real World Evidence Market Opportunity in Latin America, 2021-2030
14.4.4.5. Real World Evidence Market Opportunity in Middle East and North Africa (MENA), 2021-2030
14.4.4.6. Real World Evidence Market Opportunity in Rest of the World (RoW), 2021-2030

14.5. Concluding Remarks

15. SURVEY INSIGHTS
15.1. Chapter Overview
15.2. Analysis by Designation of Respondents
15.3. Analysis by Type of Services Offered
15.4. Analysis by Real World Data Sources
15.5. Analysis by Applications of Real World Evidence
15.6. Analysis by Key Challenges in Generating Real World Evidence
15.7. Analysis by Extent of Outsourcing
15.8. Current Annual Budget for Real World Evidence

16. IMPACT OF COVID-19 ON REAL WORLD EVIDENCE MARKET
16.1. Chapter Overview
16.2. Current Options and Recuperative Initiatives of Key Players
16.3. Impact on Real World Evidence Market Opportunity

17. CONCLUSION

18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Limor BH Epstein, Founder, Data2Life
18.3. Anonymous, Vice President, Big Pharmaceutical Company 
18.4. Wirth Peter, Vice President, RTI Health Solutions
18.5. Douglas Drake (Senior Director, Clinerion)
18.6. Fernando Santa (Chief Operating Officer, Adarna Health Data)
18.7. Jonathan Moshinsky, Head of Market Strategy, uMotif
18.8. Anonymous, Savana

19. APPENDIX 1: TABULATED DATA

20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Role of Real World Data in Shaping Healthcare Decision-making
Figure 3.2 Common Types of Chronic Disorders and their Rapidly Increasing Prevalence
Figure 3.3 Drug Development Costs: Historical Trend (USD Million)
Figure 3.4 Limitations of Randomized Clinical Trials
Figure 3.5 Traditional versus Outcome-based Development Model
Figure 3.6 Process of Generating Evidence from Real World Data
Figure 3.7 Type of Real World Data Sources
Figure 3.8 Different Constituents of Real World Data Sources
Figure 3.9 Randomized Clinical Trials versus Real World Evidence
Figure 3.10 Potential Applications of Real World Evidence
Figure 3.11 Potential Applications of Real World Evidence across Different Stages of Drug Development and Commercialization: A Summary
Figure 3.12 Growth Drivers and Potential Roadblocks of Real World Evidence
Figure 4.1 Real World Evidence: Primary Elements of Data Governance
Figure 4.2 Real World Evidence: Ideal Regulatory Framework
Figure 4.3 Emergence of Real World Evidence in China
Figure 5.1 Real World Evidence Solution Providers: Distribution by Year of Establishment
Figure 5.2 Real World Evidence Solution Providers: Distribution by Company Size
Figure 5.3 Real World Evidence Solution Providers: Distribution by Location of Headquarters
Figure 5.4 Real World Evidence Solution Providers: Distribution by Type of Business Model
Figure 5.5 Real World Evidence Solution Providers: Distribution by Type of Services Offered
Figure 5.6 Real World Evidence Solution Providers: Distribution by Real World Data Source
Figure 5.7 Real World Evidence Solution Providers: Distribution by Key Applications of Real World Evidence
Figure 5.8 Real World Evidence Solution Providers, Grid Analysis: Distribution by Company Size, Type of Offering and Applications of Real World Evidence
Figure 5.9 Real World Evidence Solution Providers: Distribution by Key Therapeutic Areas
Figure 7.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 7.3 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.5 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.6 Clinical Trial Analysis: Dot Plot of Number of Trials and Enrolled Patient Population
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.8 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Figure 7.9 Clinical Trial Analysis: Distribution by Type of Study
Figure 7.10 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Study
Figure 7.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.12 Clinical Trial Analysis: Most Active Industry Players
Figure 7.13 Clinical Trial Analysis: Most Active Non-Industry Players
Figure 7.14 Clinical Trial Analysis: Evolutionary Trends in Key Focus Areas
Figure 7.15 Clinical Trial Analysis: Distribution by Key Therapeutic Areas
Figure 7.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Key Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Leading Indications
Figure 7.18 Grid Representation: Distribution by Key Therapeutic Areas, Number of Trials and Leading Players
Figure 7.19 Clinical Trial Analysis: Year Wise Trend of Trials Conducted by Leading Industry Players, 2013-2020
Figure 7.20 Clinical Trial Analysis: Benchmarking of Leading Industry Players by Number of Trials across Key Therapeutic Areas
Figure 8.1 Publication Analysis: Distribution by Type of Publication
Figure 8.2 Publication Analysis: Cumulative Year-wise Trend, 2016-Q3 2020
Figure 8.3 Publication Analysis: Distribution by Key Focus Areas
Figure 8.4 Publication Analysis: Word Cloud of Study Titles
Figure 8.5 Publication Analysis: Distribution by Real World Data Sources
Figure 8.6 Publication Analysis: Key Indications (in Terms of Number of Published Studies)
Figure 8.7 Publication Analysis: Distribution by Type of Sponsor
Figure 8.8 Publication Analysis: Most Active Industry Players (in Terms of Number of Published Studies)
Figure 8.9 Publication Analysis: Geographical Distribution of Authors
Figure 8.10 Publication Analysis: Key Journals (in Terms of Number of Published Studies)
Figure 8.11 Publication Analysis: Key Journals (in Terms of Impact Factor)
Figure 8.12 Publication Analysis: Most Popular Authors
Figure 9.1 Trends on Social Media: Historical Activities on Twitter
Figure 9.2 Trends on Social Media: Cumulative Year-wise Distribution (in terms of Volume of Tweets)
Figure 9.3 Trends on Social Media: Most Popular Keywords
Figure 9.4 Trends on Social Media: Most Popular Real World Data Sources
Figure 9.5 Trends on Social Media: Most Popular Applications of Real World Evidence
Figure 9.6 Trends on Social Media: Most Popular Therapeutic Areas
Figure 9.7 Trends on Social Media: Most Popular Stakeholders
Figure 9.8 Trends on Social Media: Most Prolific Contributors
Figure 9.9 Trends on Social Media: Most Influential Contributors
Figure 10.1 Global Events Analysis: Cumulative Quarter-wise Trend, H1 2017-2020
Figure 10.2 Global Events Analysis: Distribution by Event Platform
Figure 10.3 Global Events Analysis: Distribution by Event Location
Figure 10.4 Global Events Analysis: Distribution by Type of Event
Figure 10.5 Global Events Analysis: Evolutionary Trend in Key Focus Areas
Figure 10.6 Global Events Analysis: Historical Trend of Event Agendas, 2017-2020
Figure 10.7 Global Events Analysis: Most Active Event Organizers
Figure 10.8 Global Events Analysis: Most Active Industry Players (in terms of Event Participation)
Figure 10.9 Global Events Analysis: Most Active Non-Industry Players (in terms of Event Participation)
Figure 10.10 Global Events Analysis: Distribution by Designations of Event Participants
Figure 10.11 Global Events Analysis: Distribution by Affiliated Departments of Event Participants
Figure 10.12 Global Events Analysis: Geographical Mapping of Upcoming Events
Figure 11.1 Comparison of Historical and Optimal Approach of Real World Evidence Generation
Figure 11.2 Stakeholder Needs Analysis: Comparison of Stakeholders
Figure 11.3 Stakeholder Needs Analysis: Distribution of Stakeholders based on Real World Data Usability
Figure 11.4 Stakeholder Needs Analysis: Comparison of Needs of Stakeholders
Figure 11.5 Stakeholder Needs Analysis: Distribution of Needs based on Current and Future Relevance
Figure 11.6 Stakeholder Needs Analysis: Needs of Healthcare Providers based on Current and Future Relevance
Figure 11.7 Stakeholder Needs Analysis: Needs of Manufacturers based on Current and Future Relevance
Figure 11.8 Stakeholder Needs Analysis: Needs of Payers based on Current and Future Relevance
Figure 11.9 Stakeholder Needs Analysis: Needs of Patients based on Current and Future Relevance
Figure 11.10 Stakeholder Needs Analysis: Needs of Regulators based on Current and Future Relevance
Figure 12.1 Key Acquisition Targets: Potential Targets in North America
Figure 12.2 Key Acquisition Targets: Potential Targets in Europe
Figure 12.3 Key Acquisition Targets: Potential Targets in Asia-Pacific and Rest of the World
Figure 12.4 Likely Acquisition Targets: Geographical Distribution
Figure 13.1 Real World Evidence: SWOT Analysis
Figure 13.2 Comparison of SWOT Factors
Figure 14.1 Global Real World Evidence Market Opportunity, 2021-2030 (USD Million)
Figure 14.2 Real World Evidence Market Opportunity, 2021-2030: Distribution by Type of Real World Data Source
Figure 14.3 Real World Evidence Market Opportunity from Medical Claims Data, 2021-2030 (USD Million)
Figure 14.4 Real World Evidence Market Opportunity from Clinical Trials Data, 2021-2030 (USD Million)
Figure 14.5 Real World Evidence Market Opportunity from Clinical Settings Data, 2021-2030 (USD Million)
Figure 14.6 Real World Evidence Market Opportunity from Patient-Powered Data, 2021-2030 (USD Million)
Figure 14.7 Real World Evidence Market Opportunity from Other Types of Data, 2021-2030 (USD Million)
Figure 14.8 Real World Evidence Market Opportunity, 2021-2030: Distribution by Therapeutic Areas
Figure 14.9 Real World Evidence Market Opportunity for Autoimmune Disorders, 2021-2030
Figure 14.10 Real World Evidence Market Opportunity for Cardiovascular Disorders, 2021-2030 (USD Million)
Figure 14.11 Real World Evidence Market Opportunity for Infectious Diseases, 2021-2030 (USD Million)
Figure 14.12 Real World Evidence Market Opportunity for Metabolic Disorders, 2021-2030 (USD Million)
Figure 14.13 Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, 2021-2030 (USD Million)
Figure 14.14 Real World Evidence Market Opportunity for Oncological Disorders, 2021-2030 (USD Million)
Figure 14.15 Real World Evidence Market Opportunity for Respiratory Disorders, 2021-2030 (USD Million)
Figure 14.16 Real World Evidence Market Opportunity for Other Types of Disorders, 2021-2030 (USD Million)
Figure 14.17 Real World Evidence Market Opportunity, 2021-2030: Distribution by Key Applications
Figure 14.18 Real World Evidence Market Opportunity in Early Stage Research, 2021-2030 (USD Million)
Figure 14.19 Real World Evidence Market Opportunity in Clinical Development, 2021-2030 (USD Million)
Figure 14.20 Real World Evidence Market Opportunity in Regulatory Approval, 2021-2030 (USD Million)
Figure 14.21 Real World Evidence Market Opportunity in Pricing / Reimbursement, 2021-2030 (USD Million)
Figure 14.22 Real World Evidence Market Opportunity in Post-Approval Studies, 2021-2030 (USD Million)
Figure 14.23 Real World Evidence Market Opportunity, 2021-2030: Distribution by Geography
Figure 14.24 Real World Evidence Market Opportunity in North America, 2021-2030 (USD Million)
Figure 14.25 Real World Evidence Market Opportunity in Europe, 2021-2030 (USD Million)
Figure 14.26 Real World Evidence Market Opportunity in Asia-Pacific, 2021-2030 (USD Million)
Figure 14.27 Real World Evidence Market Opportunity in Latin America, 2021-2030 (USD Million)
Figure 14.28 Real World Evidence Market Opportunity in MENA, 2021-2030 (USD Million)
Figure 14.29 Real World Evidence Market Opportunity in Rest of the World, 2021-2030 (USD Million)
Figure 14.30 Overall Real World Evidence Market Opportunity, Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 15.1 Survey Analysis: Distribution by Type of Company
Figure 15.2 Survey Analysis: Distribution by Location of Company
Figure 15.3 Survey Analysis: Distribution by Designation and Seniority Level of Respondents
Figure 15.4 Survey Analysis: Distribution by Types of Services Offered
Figure 15.5 Survey Analysis: Distribution by Real World Data Sources
Figure 15.6 Survey Analysis: Distribution by Applications of Real World Evidence Generation
Figure 15.7 Survey Analysis: Distribution by Key Challenges
Figure 15.8 Survey Analysis: Distribution by Extent of Outsourcing
Figure 15.9 Survey Analysis: Distribution by Average Budget Allocated by Big Pharmaceutical Companies
Figure 16.1 Real World Evidence Market, 2021-2030: COVID-19 Impact Scenario
Figure 17.1 Concluding Remarks: Current Market Landscape
Figure 17.2 Concluding Remarks: Clinical Trial Analysis
Figure 17.3 Concluding Remarks: Publication Analysis
Figure 17.4 Concluding Remarks: Global Events Analysis
Figure 17.5 Concluding Remarks: Key Acquisition Targets
Figure 17.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Primary Elements of Different Sources of Real World Data
Table 3.2 Real World Evidence: Opportunities in Pharmaceutical and Medical Device Industries
Table 3.3 Randomized Clinical Trials versus Real World Evidence
Table 5.1 Real World Evidence Solution Providers: List of Industry Players
Table 5.2 Real World Evidence Solution Providers: Information on Business Model and Service Offerings
Table 5.3 Real World Evidence Solution Providers: Information on Real World Data Sources
Table 5.4 Real World Evidence Solution Providers: Information on Applications
Table 6.1 List of Companies Profiled
Table 6.2 Clinerion: Company Snapshot
Table 6.3 Clinerion: Recent Developments and Future Outlook
Table 6.4 Clinigen Group: Company Snapshot
Table 6.5 Clinigen Group: Recent Developments and Future Outlook
Table 6.6 Cognizant Analytics: Company Snapshot
Table 6.7 Cognizant Analytics: Recent Developments and Future Outlook
Table 6.8 Evidera: Company Snapshot
Table 6.9 Evidera: Recent Developments and Future Outlook
Table 6.10 HealthCore: Company Snapshot
Table 6.11 HealthCore: Recent Developments and Future Outlook
Table 6.12 IBM: Company Snapshot
Table 6.13 IBM: Recent Developments and Future Outlook
Table 6.14 ICON: Company Snapshot
Table 6.15 ICON: Recent Developments and Future Outlook
Table 6.16 IQVIA: Company Snapshot
Table 6.17 IQVIA: Recent Developments and Future Outlook
Table 6.18 Medpace: Company Snapshot
Table 6.19 Medpace: Recent Developments and Future Outlook
Table 6.20 NorthWest EHealth: Company Snapshot
Table 6.21 NorthWest EHealth: Recent Developments and Future Outlook
Table 6.22 Optum Insight: Company Snapshot
Table 6.23 Optum Insight: Recent Developments and Future Outlook
Table 6.24 Oracle: Company Snapshot
Table 6.25 Oracle: Recent Developments and Future Outlook
Table 6.26 PAREXEL: Company Snapshot
Table 6.27 PAREXEL: Recent Developments and Future Outlook
Table 6.28 Perkin Elmer: Company Snapshot
Table 6.29 Perkin Elmer: Recent Developments and Future Outlook
Table 6.30 SAS: Company Snapshot
Table 6.31 SAS: Recent Developments and Future Outlook
Table 6.32 Syneos Health: Company Snapshot
Table 6.33 Syneos Health: Recent Developments and Future Outlook
Table 6.34 TriNetX: Company Snapshot
Table 6.35 TriNetX: Recent Developments and Future Outlook
Table 7.1 List of Leading Clinical Trials by Enrolled Patient Population
Table 7.2 List of Clinical Trials for COVID-19
Table 10.1 List of Global Events Related to Real World Evidence, 2017-2020
Table 14.1 List of Use Cases Related to Real World Evidence, 2016-2020
Table 15.1 Survey Analysis: Overview of Respondents
Table 15.2 Survey Analysis: Designation and Seniority Level of Respondents
Table 15.3 Survey Analysis: Types of Services Offered
Table 15.4 Survey Analysis: Real World Data Sources
Table 15.5 Survey Analysis: Applications of Real World Evidence
Table 15.6 Survey Analysis: Key Challenges
Table 15.7 Survey Analysis: Extent of Outsourcing
Table 15.8 Survey Analysis: Average Budget Allocated by Big Pharmaceutical Companies
Table 16.1 FDA Issued COVID-19 Projects Related to Real World Evidence
Table 18.1 Data2Life: Company Snapshot
Table 18.2 Adarna Health Data: Company Snapshot
Table 18.3 RTI Health Solutions: Company Snapshot
Table 18.4 Clinerion: Company Snapshot
Table 18.5 uMotif: Company Snapshot
Table 18.6 Savana: Company Snapshot
Table 19.1 Drug Development Costs: Historical Trend (USD Million)
Table 19.2 Real World Evidence Solution Providers: Distribution by Year of Establishment
Table 19.3 Real World Evidence Solution Providers: Distribution by Company Size
Table 19.4 Real World Evidence Solution Providers: Distribution by Location of Headquarters
Table 19.5 Real World Evidence Solution Providers: Distribution by Type of Business Model
Table 19.6 Real World Evidence Solution Providers: Distribution by Type of Services Offered
Table 19.7 Real World Evidence Solution Providers: Distribution by Real World Data Sources
Table 19.8 Real World Evidence Solution Providers: Distribution by Key Applications
Table 19.9 Tree Map Representation: Distribution by Company Size and Applications of Real World Evidence
Table 19.10 Real World Evidence Solution Providers: Distribution by Key Therapeutic Areas
Table 19.11 Clinical Trial Analysis: Distribution by Trial Status
Table 19.12 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 19.13 Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 19.14 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 19.15 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 19.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 19.17 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Table 19.18 Clinical Trial Analysis: Distribution by Type of Study
Table 19.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Type of Study
Table 19.20 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.21 Clinical Trial Analysis: Most Active Industry Players
Table 19.22 Clinical Trial Analysis: Most Active Non-Industry Players
Table 19.23 Clinical Trial Analysis: Distribution by Key Therapeutic Areas
Table 19.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Key Therapeutic Areas
Table 19.25 Clinical Trial Analysis: Leading Indications
Table 19.26 Clinical Trial Analysis: Year Wise Trend of Trials Conducted by Leading Industry Players, 2013-2020
Table 19.27 Clinical Trial Analysis: Benchmarking of Leading Industry Players by Number of Trials Across Key Therapeutic Areas
Table 19.28 Publication Analysis: Distribution by Type of Publication
Table 19.29 Publication Analysis: Cumulative Year-wise Trend, (2016-Q3 2020)
Table 19.30 Publication Analysis: Distribution by Key Focus Areas
Table 19.31 Publication Analysis: Distribution by Real World Data Sources
Table 19.32 Publication Analysis: Key Indications in Terms of Number of Published Studies
Table 19.33 Publication Analysis: Distribution by Type of Sponsors
Table 19.34 Publication Analysis: Most Active Industry Players in Terms of Number of Published Studies
Table 19.35 Publication Analysis: Geographical Distribution of Authors
Table 19.36 Publication Analysis: Key Journals (in Terms of Number of Published Studies)
Table 19.37 Publication Analysis: Key Journals by Impact Factor (In Terms of Impact Factor)
Table 19.38 Publication Analysis: Most Popular Authors
Table 19.39 Trends on Social Media: Cumulative Year-wise Analysis by Volume of Tweets, 2013-H1 2018
Table 19.40 Global Events Analysis: Cumulative Half Year-wise Trend, H1 2017-2021
Table 19.41 Global Events Analysis: Distribution by Event Platform
Table 19.42 Global Events Analysis: Distribution by Event Location
Table 19.43 Global Events Analysis: Distribution by Type of Event
Table 19.44 Global Events Analysis: Most Active Event Organizers
Table 19.45 Global Events Analysis: Most Active Industry Players (in terms of Event Participation
Table 19.46 Global Events Analysis: Most Active Non-Industry Players (in terms of Event Participation
Table 19.47 Global Events Analysis: Distribution by Designations of Event Participants
Table 19.48 Global Events Analysis: Distribution by Affiliated Departments of Event Participants
Table 19.49 Global Real World Evidence Market Opportunity, 2021-2030 (USD Million)
Table 19.50 Real World Evidence Market Opportunity, 2021-2030: Distribution by Different Type of Real World Data Sources
Table 19.51 Real World Evidence Market Opportunity from Medical Claims Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.52 Real World Evidence Market Opportunity from Clinical Trials Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.53 Real World Evidence Market Opportunity from Clinical Settings Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.54 Real World Evidence Market Opportunity from Patient-Powered Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.55 Real World Evidence Market Opportunity from Other Types of Data, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.56 Real World Evidence Market Opportunity, 2021-2030: Distribution by Therapeutic Areas
Table 19.57 Real World Evidence Market Opportunity for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.58 Real World Evidence Market Opportunity for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.59 Real World Evidence Market Opportunity for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.60 Real World Evidence Market Opportunity for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.61 Real World Evidence Market Opportunity for Neurological / Psychiatric Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.62 Real World Evidence Market Opportunity for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.63 Real World Evidence Market Opportunity for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.64 Real World Evidence Market Opportunity for Other Types of Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.65 Real World Evidence Market Opportunity, 2021-2030: Distribution by Key Applications
Table 19.66 Real World Evidence Market Opportunity in Early Stage Research, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.67 Real World Evidence Market Opportunity in Clinical Development, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.68 Real World Evidence Market Opportunity in Regulatory Approval, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.69 Real World Evidence Market Opportunity in Pricing / Reimbursement, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.70 Real World Evidence Market Opportunity in Post-Approval Studies, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.71 Real World Evidence Market Opportunity, 2021-2030: Distribution by Geography
Table 19.72 Real World Evidence Market Opportunity in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.73 Real World Evidence Market Opportunity in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.74 Real World Evidence Market Opportunity in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.75 Real World Evidence Market Opportunity in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.76 Real World Evidence Market Opportunity in MENA, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.77 Real World Evidence Market Opportunity in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.78 Overall Real World Evidence Market Opportunity, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.79 Survey Analysis: Distribution by Type of Organization
Table 19.80 Survey Analysis: Distribution by Location of Organization
Table 19.81 Survey Analysis: Distribution by Seniority Level
Table 19.82 Survey Analysis: Distribution by Types of Services Offered
Table 19.83 Survey Analysis: Distribution by Real World Data Sources
Table 19.84 Survey Analysis: Distribution by Applications of Real World Evidence Generation
Table 19.85 Survey Analysis: Distribution by Key Challenges
Table 19.86 Survey Analysis: Distribution by Extent of Outsourcing
Table 19.87 Survey Analysis: Distribution by Average Budget Allocated by Big Pharmaceutical Companies

List Of Companies

The following companies / organizations have been mentioned in this report.

1. 2 GL Outsourcing
2. 23andMe
3. 8KMiles
4. AbbVie
5. Acceliant
6. Accenture
7. Accsight
8. Adarna Health Data
9. Adelphi Real World
10. Advera Health Analytics
11. Aetion
12. AG Mednet
13. Aixial
14. Akeso Medical Holdings
15. Allergan
16. Allscripts
17. Alpha MD
18. AMA Innovation Lab
19. Amazon Web Services
20. American College of Cardiology
21. Amgen
22. Ana Health
23. Anne Arundel Medical Center
24. Anthem
25. Arcana Institute
26. Arena International Events
27. Arm
28. AstraZeneca
29. ASUS Life
30. ATAI Life Sciences
31. Atrium Health
32. Axonal-Biostatem
33. Axtria
34. Bayer
35. BC Platforms
36. Beth Israel Deaconess Medical Center
37. Bio Valley
38. Biocruces Bizkaia Health Reseach Institute
39. Bioserv
40. Boehringer Ingelheim
41. Boston Health Economics 
42. Boston Scientific Corporation
43. Boston University
44. Bridge Medical
45. Brigham and Women's Hospital
46. Bristol-Myers Squibb
47. Cambridge Healthtech Institute
48. Cambridgeshire Community Reuse and Recycling Network
49. Carevive
50. CB Insights
51. CBI Events
52. Cegedim Strategic Data (CSD)
53. Celeri Health
54. Centers for Disease Control and Prevention
55. Centre Hospitalier Intercommunal Robert Ballanger
56. Certara
57. CHA Medical Group
58. Chinese Biopharmaceutical Association 
59. Ciox Health
60. Cisiv
61. CitiusTech
62. CK Aspire
63. Clarivate Analytics
64. Cleveland Clinic
65. Clinakos
66. ClinaMetrics
67. Clinerion
68. Clinical Practice Research Datalink
69. Clinical Trial EndPoint
70. Clinigen Group
71. Cloudera
72. CloudMoyo
73. Cluell
74. Cogentia Healthcare Consulting
75. Cognizant 
76. conferenceseries.com
77. ConvergeHEALTH by Deloitte
78. Corrona
79. Cota Healthcare
80. Covance
81. Crossix Solutions
82. CSS
83. CTI Clinical Trial and Consulting Services
84. Custodix
85. Cytel
86. D Cube Analytics
87. Daiichi Sankyo
88. Dartmouth-Hitchcock Medical Center
89. Data2Life
90. Databricks
91. Datavant
92. DCC 
93. Decision Driver Analytics
94. Decision Resources Group
95. Dendrite Clinical Systems
96. DHIS2
97. DIGIPHARM
98. Digital Health Labs
99. Diplomat
100. docdok.health
101. Dresden International University
102. Drug Information Association
103. Drug Intelligence
104. Duke Company
105. Duke University
106. Duke-Margolis Center for Health Policy
107. Duke-NUS Medical School
108. DuPage Medical Group
109. eClinical Forum
110. Econcare
111. Eli Lilly
112. Elligo Health Research
113. Ephicacy
114. EPID Research
115. EPM Group
116. ERN GUARD-Heart
117. Ernst & Young Global
118. ESiOR
119. EUCROF
120. European Medicines Agency
121. European Society of Cardiology
122. EVERSANA
123. Evex Medical
124. Evidence Based Solutions
125. Evidera
126. Evidilya
127. Excelra
128. ExL Events 
129. eyeforpharma
130. Financial Times
131. Flatiron Health
132. Flex
133. Food and Drug Law Institute 
134. Friends of Cancer Research
135. Fuzzy Logix
136. Gate2Biotech
137. Genentech
138. Genospace
139. GlaxoSmithKline
140. GNS Healthcare
141. Graticule
142. GSK
143. Hanson Wade
144. Happy Life Technology
145. Harvard Medical School
146. Harvard Pilgrim Health Care Institute 
147. Healiant
148. Healint
149. Health Canada
150. Health IQ
151. Health Solutions
152. Health Technology Assessment international
153. Healthagen
154. Healthcare Information and Management Systems Society
155. HealthCore
156. Healthing Research
157. HealThink
158. HealthVerity
159. Hospital Clinic of Barcelona
160. Hospital Costa del Sol
161. Hospital de Basurto
162. Hospital del Mar
163. Hospital Galdakao-Usansolo
164. Hospital São Domingos
165. Hospital Universitario Araba
166. Hospital Universitario Donostia
167. Houston Methodist Hospital 
168. Huron
169. IBC Asia
170. IBM Watson Health (IBM)
171. iClusion
172. ICON
173. Idorsia
174. IEEE
175. Ignite Data
176. IMI GetReal
177. Imperial College Health Partners
178. Indegene
179. Infosys
180. Ingress Health
181. Innovation Enterprise
182. Inovalon
183. Insight Pharma Services
184. Institute of Statistical, Social and Economic Research
185. Instituto de Salud Carlos III
186. Intel
187. Inteliquet
188. International Business Machines
189. International Center for Entrepreneurial Development
190. International Coalition of Medicines Regulatory Authorities
191. International Society for Pharmacoeconomics and Outcomes Research
192. International Society for Pharmacoeconomics and Outcomes Research
193. IntrinsiQ Specialty Solutions
194. IQVIA
195. Istituto Auxologico Italiano
196. iTakeControl
197. iwantGreatCare
198. Janssen
199. JDRF
200. Johaus Global
201. Johns Hopkins University
202. Kaiku Health
203. Kaiser Permanente
204. Kantar Health
205. Keyrus Biopharma
206. KNect365
207. Koneksa Health
208. Kx Systems
209. LINK Medical Research
210. LMC Manna Research
211. London School of Economics and Political Science
212. LynxCare
213. M2Gen
214. M2S
215. MA Provider
216. MakroCare
217. MAP BioPharma
218. MAP Group (Acquired by ICON)
219. marcus evans
220. MarketsandMarkets
221. MarkLogic
222. MarksMan Healthcare Communications
223. Massachusetts General Hospital
224. Massachusetts Institute of Technology  
225. MaxisIT
226. Mayo Clinic
227. McDougall Scientific
228. McKesson
229. MDC Partners
230. MeaningCloud
231. Medaffcon
232. Med-e Share
233. MedEngine
234. Medialis
235. Medical College of Wisconsin
236. Medical Wisdom Consulting Group
237. Medidata
238. Medimix International (Acquired by Evidera)
239. MeDiNova Research
240. Medlior Health Outcomes Research 
241. Medpace
242. MedPass International 
243. MedSoft
244. Medstreaming
245. Medtronic
246. Medway NHS Foundation Trust
247. Meiji Pharmaceutical University 
248. Merck
249. Mercy Technology Services
250. Metaforms
251. Methodist Health System
252. Model Answers 
253. MolecularMD (Acquired by ICON)
254. MyOwnMed
255. National Association of Managed Care Physicians 
256. National Cancer Institute
257. National Health Service Trust
258. National Institute for Health and Care Excellence
259. National Institutes of Health
260. National Research Center for Preventive Medicine
261. Neox
262. Noona
263. Nordic HTA
264. Northern Alberta Clinical Trials and Research Centre
265. NorthWest EHealth
266. Novartis
267. Novo Nordisk
268. Numerus
269. NYU Langone Health
270. O4 Research
271. Observational & Pragmatic Research Institute
272. Odysseus Data Services
273. OKRA Technologies
274. OM1
275. Omega CRO
276. Oncocare Health Incorporated
277. OncoStats
278. OPEN Health
279. Optra Systems
280. OptumInsight
281. Opyl
282. Oracle
283. OrbitalRX
284. Oriola
285. ORPHA Strategy Consulting
286. Orphazyme
287. OXON Epidemiology
288. Palantir
289. PAREXEL
290. Patient iP
291. PatientsLikeMe
292. PatientSource
293. PCORnet
294. Pentavere
295. Peripharm
296. PerkinElmer
297. Pfizer
298. pH Associates
299. Pharma Industry Finland
300. Pharma Intelligence
301. Pharmaceuticals and Medical Devices Agency (PMDA)
302. PharmaLand Consulting Group
303. Pharmerit International
304. PHARMO Institute for Drug Outcomes Research
305. phUSE
306. Pitié-Salpêtrière University Hospital
307. Point-of-Care Partners
308. PotentiaMED
309. PRA Health Sciences
310. Precision Digital Health
311. Premier
312. Provisio
313. Public Health England
314. Qlik
315. Quantify Research
316. Quantzig
317. Raven Biosciences
318. Real Consulting Data
319. REAL Europe
320. Real Life Sciences
321. RealHealthData
322. Reuters Events
323. Roam
324. Roche
325. RTI Health Solutions
326. RWE Genesys
327. RxAnte
328. S3 Connected Health
329. S4 Research
330. Saama Technologies
331. Sanofi
332. Sino-American Pharmaceutical Professionals Association -Greater Philadelphia 
333. Sapungo
334. SAS
335. Savana
336. Sciformix
337. Self Care Catalysts
338. Semicrol
339. Sentry Data Systems
340. SerenaGroup
341. SHYFT Analytics
342. SmartAnalyst
343. SMi Group
344. Society for Clinical Research Sites
345. Southwood Research
346. Spanish Data Protection Agency
347. SPRIM Advanced Life Sciences
348. SQN Clinical 
349. St George's University Hospitals NHS Foundation Trust
350. Stanford University
351. StatFinn
352. Strategy Institute
353. SVMPharma
354. Syapse
355. Symphony Health Solutions
356. Syneos Health
357. Synergus
358. Syntel
359. Takeda Pharmaceuticals
360. Talking Medicines
361. Talosix
362. Target RWE
363. TCD Outcomes Research
364. TCD Research
365. TCR Solutions
366. Techtrials International
367. Tempus
368. Terrapinn Holdings
369. TFS
370. Accelerated Cure Project
371. The Association of the Pharmaceutical Industry in Norway
372. European Epidemiological Forum
373. The Evidence Base
374. The Health and Medicine Division
375. The National Patient-Centered Clinical Research Network 
376. The Wound Treatment Center
377. Thomas Jefferson University
378. TriNetX
379. Trinity Industries
380. T-Systems
381. TTi Healthcare and Economics
382. Tufts Center for the Study of Drug Development
383. Turacoz Healthcare Solutions
384. U.S. Department of Veterans Affairs
385. UCSF-Stanford Center of Excellence in Regulatory Science and Innovation
386. uMotif
387. United BioSource (UBC)
388. United States Food and Drug Administration
389. University College London
390. University Hospitals
391. University Hospital of the Nuestra Senora de Candelaria
392. University of Amsterdam
393. University of California
394. University of Cambridge
395. University of Colorado
396. University of Ghana
397. University of Michigan
398. University of Minnesota
399. University of North Carolina
400. University of Pennsylvania
401. University of Pittsburgh
402. University of Southern California
403. University of Wisconsin
404. VA Office of Research and Development
405. Validic
406. Vecna
407. Verana Health
408. Verantos
409. Verily Life Sciences
410. Vestrum Health
411. Vitaccess
412. Vital Statistics Consulting
413. Vonlanthen Group
414. Wake Forest University Health Sciences
415. Wellframe
416. West Monroe Partners
417. William Beaumont Hospital
418. Wipro
419. World Congress
420. Worldwide Clinical Trials
421. Xcenda
422. xCures
423. Yale University
424. Zeblok
425. ZEINCRO
426. Zem Solutions
427. Zephyr Health
428. ZM Company
429. ZS Company

Source 1: www.intel.com/content/dam/www/public/us/en/documents/solution-briefs/ai-and-wearables-bring-new-data-and-analytics-to-clinical-trials-solution-brief.pdf
Source 2: www.fda.gov/regulatory-information/selected-amendments-fdc-act/21st-century-cures-act#:~:text=The%2021st%20Century%20Cures%20Act,them%20faster%20and%20more%20efficiently